Manhattan Scientifics, Inc.
MHTX · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | 0% | 0% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | -1,358% | -1,374% | -1,350% |
| Other Income/Exp. Net | -$0 | -$2 | -$3 | $5 |
| Pre-Tax Income | -$1 | -$3 | -$4 | $4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$3 | -$4 | $4 |
| % Margin | – | -5,460% | -7,278% | 8,628% |
| EPS | -0.002 | -0.005 | -0.007 | 0.008 |
| % Growth | 57.1% | 24.6% | -184.4% | – |
| EPS Diluted | -0.002 | -0.005 | -0.007 | 0.007 |
| Weighted Avg Shares Out | 559 | 559 | 559 | 558 |
| Weighted Avg Shares Out Dil | 559 | 559 | 559 | 593 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$3 | -$4 | $4 |
| % Margin | – | -5,412% | -7,222% | 8,682% |